Insider · CIK 0001947184
Melissa Tosca
Files at KPRX (KIORA PHARMACEUTICALS INC). First filing -, latest -.
Melissa Tosca files SEC Form 4 as CFO at KPRX (KIORA PHARMACEUTICALS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Melissa Tosca has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | KPRX KIORA PHARMACEUTICALS INC | FTax withholding Common Stock | -911 | $2.66 | $2,423 | 26,064 | Jul 2, 2026 |
| Apr 1, 2026 | KPRX KIORA PHARMACEUTICALS INC | FTax withholding Common Stock | -929 | $1.95 | $1,812 | 26,975 | Apr 2, 2026 |
| Mar 6, 2026 | KPRX KIORA PHARMACEUTICALS INC | AGrant or award Common Stock | +6,533 | $0.00 | $0 | 27,904 | Mar 10, 2026 |
| Mar 6, 2026 | KPRX KIORA PHARMACEUTICALS INC | AGrant or award Stock Option (right to buy)derivative | +13,067 | $0.00 | $0 | 13,067 | Mar 10, 2026 |
| Apr 1, 2025 | KPRX KIORA PHARMACEUTICALS INC | AGrant or award Common Stock | +7,772 | $0.00 | $0 | 21,371 | Apr 2, 2025 |
| Apr 1, 2025 | KPRX KIORA PHARMACEUTICALS INC | AGrant or award Stock Option (right to buy)derivative | +15,543 | $0.00 | $0 | 15,543 | Apr 2, 2025 |
Questions about Melissa Tosca
Answered from the filings on this page, as of the latest one.
Is Melissa Tosca buying or selling?
Melissa Tosca has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Melissa Tosca's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Melissa Tosca has 0.
Where does Melissa Tosca file Form 4?
Melissa Tosca has filed Form 4 at KPRX (KIORA PHARMACEUTICALS INC) as CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.